Filana Therapeutics, Inc.: 10-Q filed 2020-05-06

Name: Filana Therapeutics, Inc.: 10-Q filed 2020-05-06
Creator: Filana Therapeutics, Inc.

What Filana Therapeutics, Inc. reported in its quarterly report filed 2020-05-06 (fiscal Q1 2020): 26 published measures, 57 facts as tagged in accession 0001069530-20-000032.

This filing

Form: 10-Q (quarterly report)
Filed: 2020-05-06
Fiscal period: fiscal Q1 2020
Accession: 0001069530-20-000032 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Filana Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2020-03-31	25,977,000	USD
At 2019-12-31	23,486,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2020-03-31	1,145,000	USD
At 2019-12-31	1,387,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2020-03-31	24,832,000	USD
At 2019-12-31	22,099,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2020-03-31	25,600,000	USD
At 2019-12-31	23,081,000	USD
At 2019-03-31	19,125,000	USD
At 2018-12-31	19,807,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	-1,150,000	USD	91
2019-01-01 to 2019-03-31	-1,359,000	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	-1,194,000	USD	91
2019-01-01 to 2019-03-31	-604,000	USD	90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	18,000	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	3,613,000	USD	91
2019-01-01 to 2019-03-31	-60,000	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	100,000	USD	91
2019-01-01 to 2019-03-31	-18,000	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2020-03-31	-169,737,000	USD
At 2019-12-31	-168,587,000	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	0	USD	91
2019-01-01 to 2019-03-31	0	USD	90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2020-03-31	33,000	USD
At 2019-12-31	47,000	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	270,000	USD	91
2019-01-01 to 2019-03-31	344,000	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	-1,222,000	USD	91
2019-01-01 to 2019-03-31	-1,451,000	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2020-03-31	25,877,000	USD
At 2019-12-31	23,349,000	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2020-03-31	1,145,000	USD
At 2019-12-31	1,387,000	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2020-03-31	608,000	USD
At 2019-12-31	453,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	1,222,000	USD	91
2019-01-01 to 2019-03-31	1,451,000	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit
At 2020-03-31	24,729,902	shares
At 2019-12-31	21,841,810	shares
At 2019-03-31	17,219,300	shares
At 2018-12-31	17,219,300	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2020-03-31	194,544,000	USD
At 2019-12-31	190,664,000	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2020-03-31	24,832,000	USD
At 2019-12-31	22,099,000	USD
At 2019-03-31	18,553,000	USD
At 2018-12-31	19,628,000	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2020-03-31	67,000	USD
At 2019-12-31	90,000	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2020-03-31	387,000	USD
At 2019-12-31	777,000	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	778,000	USD	91
2019-01-01 to 2019-03-31	877,000	USD	90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	14,000	USD	91
2019-01-01 to 2019-03-31	17,000	USD	90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	155,000	USD	91
2019-01-01 to 2019-03-31	201,000	USD	90

Inspect the source

Entity: Filana Therapeutics, Inc. / CIK 0001069530
Captured: 2026-09-20T05:19:22.728Z
SEC response SHA-256: 98fbf2ec9e4273c7c7ff1d5342c79c5958c86b1e088e060391ccaf7c9ba8ef57

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001069530.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))